A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

Inclusion Criteria:

- Diagnosis of RA for >= 3 months.

- Subjects must have been on oral or parenteral MTX therapy >= 3 months and on a stable
dose for >= 4 weeks prior to first dose of study drug.

- Must have discontinued all conventional synthetic disease-modifying anti-rheumatic
drugs (csDMARDs) (other than MTX) >= 4 weeks prior to first dose of study drug.

- Meets the following minimum disease activity criteria: >= 6 swollen joints (based on
66 joint counts) and >= 6 tender joints (based on 68 joint counts) at Screening and
Baseline Visits.

Exclusion Criteria:

- Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
tofacitinib, baricitinib, and filgotinib).

- Prior exposure to any biological disease-modifying anti-rheumatic drugs (bDMARDs).

- Current diagnosis of inflammatory joint disease other than RA. Current diagnosis of
secondary Sjogren's Syndrome is permitted.